4Zalewski A,Nelson JJ,Hegg L,et al.LP-PLA2:a new kid on the block[J].Clin Chem,2006,52(9):1645-1650.
5Brilakis ES,Khera A,McGuire DK,et al.Influence of race and sex on lipoprotein-associated phospholipase A2 levels:observations from the Dallas heart study[J].Atherosclerosis,2008,199(1):110-115.
6M(o)ckel M,Müller R,Vollert JO,et al.Lipoprotein-associated phospholipase A2 for early risk stratification in patients with suspected acute coronary syndrome:a multi-marker approach:the north Wuerttemberg and Berlin infarction study-Ⅱ (NOBIS-Ⅱ)[J].Clin Res Cardiol,2007,96(9):604-612.
7O′Donoghue M,Morrow DA,Sabatine MS,et al.Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction) trial[J].Circulation,2006,113(14):1745-1752.
8Vickers KC,Maguire CT,Wolfert R,et al.Rela-tionship of lipoprotein-associated phospholipase A2 and oxidized low density lipoprotein in carotid atherosclerosis[J].J Lipid Res,2009,50(9):1735-1743.
3CORSETTI J P, RAINWATER D L, MOSS A J, et al. High lipoprotein-associated phospholipase A2 is a risk factor for recurrent coronary events in postinfarction patients [J]. ClinChem, 2006, 52 (7): 1331-1338.
4BRILAKIS E S, MCCONNELL J P, LENNON R J, et al. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up[J]. Eur Heart J, 2005, 26 (2) : 137-144.
6NAGHAVI M, LIBBY P, FALK E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part Ⅰ [ J ]. Circulation, 2003, 108 (14) : 1664-1672.
7MINTZ G S, NISSEN S E, ANDERSON W D, et al. American College of Cardiology clinical expert consensus document on standards for acquisition, measurement and reporting of intravascular ultrasound studies (ivus). A report of the american college of cardiology task force on clinical expert consensus documents developed in collaboration with the european society of cardiology endorsed by the society of cardiac angiography and interventions [ J ]. J Am Coll Cardiol, 2001, 37 (5) : 1478-1492.
8DE KORTE C L, SIEREVOGEL M J, MASTIK F, et al. Identification of atherosclerotic plaque components with intravascular ultrasound elastography in vivo: a Yucatan pig study[J]. Circulation, 2002, 105(14): 1627-1630.
9BALLANTYNE C M, HOOGEVEEN R C, BANG H, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study [ J ]. Circulation, 2004, 109 (7): 837-842.
10Keiji Tabuchi,Zenya Ito,Shigeki Tsuji,Tetsuro Wada,Kazuhiko Takahashi,Akira Hara,Tetsuro Wada,KazuhikoTakahashi,Akira Hara,Jun Kusakari. The contribution of phospholipase A2 to the cochlear dysfunction induced by transient ischemia[J]. Hearing Research,20
3Ross R. Atherosclerosis: an inflammatory disease [ J]. N Engl J Med,1999,340(2) :115 -126.
4Armstrong EJ,Morrow DA,Sabatine MS. Inflammatory biomarkers in a-cute coronary syndromes : part II : acute - phase reactants and biomark-ers ofendothelial cell activation. Circulation ,2006,113(8) : 152 -155.
5Li JJ,Fang CH. C - reactive protein is not only an inflammatory maker-but also a direct cause of cardiovascular diseases. Medicalhypotheses,2004,62:499-506.
6Ishikawa T,Imamura T,Hatakeyama K,Date H,Nagoshi T, KawamotoR,Matsuyama A,Asada Y,Eto T. Possible contribution of C - reactive-protein within coronary plaque to increasing its own plasma ievelsacrosscoronary circulation. The American Journal of cardiology,2004,93 :611-614.
7Oei HH, van der Meer IM, Hofman A,et al. Lipoprotein - associated-phospholipase A2 activity is associated with risk of coronary heartdis-ease and ischemic stroke : the Rotterdam Study. Circulation,2005,111:570 -575.
8Corson MA,Jones PH, Davidson MH. Review of the evidence for the-Clinical utility of lipoprotein - associated phospholipase A2 as acardio-vascular risk marker. Am J Cardiol,2008,101 :41F -51F.
9Garza CA, Montori VM, McConnell JP,et al. Association betweenLi-poprotein associated phosphorlipase A2 and cardiovasculardisease : asystematic review. Mayo Clin Proceedings ,2007 ,82 : 159 - 165.
